Skip to main
AYTU
AYTU logo

Aytu BioScience (AYTU) Stock Forecast & Price Target

Aytu BioScience (AYTU) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aytu BioPharma Inc. presents an attractive investment case due to its current favorable valuation and significant upside potential as indicated by a NPV analysis. The company is poised for growth with the anticipated launch of its new EXXUA drug targeting major depressive disorder (MDD) in Q4 2025, which is expected to drive revenue and enhance market presence. Additionally, clinical trials have shown that EXXUA demonstrates considerable efficacy in improving depression symptoms with a favorable side effect profile, further solidifying the company’s competitive edge in the pharmaceutical landscape.

Bears say

Aytu BioPharma is characterized by significant challenges reflected in its current trading position, as the stock is noted to be trading well below potential future sales estimates, indicating underlying concerns about its market performance. Despite the presence of a promising therapeutic pipeline and large market opportunities, the company faces substantial risks stemming from high competition and unmet medical needs within the industry, particularly in the domain of antidepressants. Additionally, the dependence on third-party sales channels could hinder Aytu BioPharma's growth trajectory, contributing to a cautious outlook regarding its financial stability and long-term viability.

Aytu BioScience (AYTU) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aytu BioScience and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aytu BioScience (AYTU) Forecast

Analysts have given Aytu BioScience (AYTU) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Aytu BioScience (AYTU) has a Strong Buy consensus rating as of Dec 11, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aytu BioScience (AYTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.